SCHEMBL1470461

SCHEMBL1470461

O=C(O)CC1CCc2ccccc21

nearest known ligand 0.62

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.62
PPARD Q03181 12/20 0.58
MTNR1A P48039 1/20 0.51
MTNR1B P49286 1/20 0.51
HTR6 P50406 1/20 0.49
PPARA Q07869 4/20 0.47
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7845908 1.00 FFAR1 (0.62) FFAR1PPARDMTNR1AMTNR1BHTR6
SCHEMBL7847075 1.00 FFAR1 (0.62) FFAR1PPARDMTNR1AMTNR1BHTR6
SCHEMBL30301824 0.90 FFAR1 (0.52) FFAR1PPARD
SCHEMBL3590904 0.90 FFAR1 (0.52) FFAR1PPARD
SCHEMBL3246802 0.88 FFAR1 (0.51) FFAR1PPARD
SCHEMBL11732903 0.86 MTNR1A (0.49) FFAR1PPARDMTNR1AMTNR1BHTR6
SCHEMBL1567606 0.86 MTNR1A (0.51) FFAR1PPARDMTNR1AMTNR1BHTR6
SCHEMBL7296740 0.84 MTNR1A (0.50) FFAR1PPARDMTNR1AMTNR1BHTR6
SCHEMBL14356155 0.84 MTNR1B (0.50) FFAR1PPARDMTNR1AMTNR1BHTR6
SCHEMBL4714587 0.84 HTR6 (0.51) FFAR1PPARDMTNR1AMTNR1BHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230364244-A1 DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY Ashvattha Therapeutics, Inc. (US) 2023-11-16 US claimed
CN-116249558-A Dendrimer compositions and methods for drug delivery to injured kidneys 阿什瓦塔治疗股份有限公司 2023-06-09 CN claimed
EP-4181913-A1 DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY Ashvattha Therapeutics, Inc. (US) 2023-05-24 EP claimed
US-5929078-A ANTISEROTONINE AGENT SYNTHELABO (FR) 1999-07-27 US claimed
JP-5085999-A None JP disclosed
CN-119923389-A 2-Substituted piperidine derivative, preparation method and medical application thereof 江苏豪森药业集团有限公司 2025-05-02 CN disclosed
CN-119219639-A Fused polycyclic compounds, process for their preparation and their pharmaceutical use 江苏豪森药业集团有限公司 2024-12-31 CN disclosed
CN-119156393-A Cyclic compound, preparation method and medical application thereof 翰森生物有限责任公司 2024-12-17 CN disclosed
CN-118900917-A Bicyclic heterocycles and ligands thereof for targeted delivery of therapeutic agents 翰森生物有限责任公司 2024-11-05 CN disclosed
CN-118696037-A Azacyclic amide derivatives, preparation method and medical application thereof 翰森生物有限责任公司 2024-09-24 CN disclosed
CN-118510765-A Piperidinyl indole derivatives, preparation method and medical application thereof 翰森生物有限责任公司 2024-08-16 CN disclosed
CN-115052596-B ADAMTS inhibitor, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2024-06-14 CN disclosed
EP-0395199-A1 Substituted tetrahydroindane derivatives and their use as intermediates INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1990-10-31 EP disclosed
EP-0372484-A2 Condensed benzene derivative ZERIA PHARMACEUTICAL CO., LTD. (JP) 1990-06-13 EP disclosed
US-4933319-A Substituted tetrahydroindane derivatives and organoleptic uses of substituted tetrahydroindanes INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1990-06-12 US disclosed
US-4902840-A Substituted tetrahydroindane derivatives and organoleptic uses of substituted tetrahydroindanes INTERNATIONAL FLAVORS AND FRAGRANCES INC. (US) 1990-02-20 US disclosed
US-4152527-A 15-Substituted-ω-pentanorprostaglandins PFIZER INC. (US) 1979-05-01 US disclosed
US-4127578-A Diene intermediates for indantetrols E. R. SQUIBB & SONS, INC. (US) 1978-11-28 US disclosed
US-4092318-A HYPOTENSIVES E. R. SQUIBB & SONS, INC. (US) 1978-05-30 US disclosed
US-4044040-A HYPERTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1977-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230364244-A1 DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY TO INJURED KIDNEY PPARA, PPARD, PPARG FFAR1 97/4885PPARD 2/4885MTNR1A 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.